Monday, 31 August 2026European Markets

NORDIC NANOVECTOR Stock Is 9% Down So Far Today

Loading stream...

(VIANEWS) - Shares of NORDIC NANOVECTOR (Oslo Børs Benchmark Index_GI: NANOV.OL) slid 9.35% to kr2.43 at 14:37 EST on Tuesday, after five successive sessions in a row of gains. Oslo Børs Benchmark Index_GI is jumping 0.13% to kr1,233.55, following the last session's downward trend. This seems, as yet, a somewhat up trend exchanging session today.

NORDIC NANOVECTOR's last close was kr2.68, 65.62% below its 52-week high of kr7.78.

About NORDIC NANOVECTOR

Nordic Nanovector ASA, a biopharmaceutical company, develops therapeutics for hematological cancers in Norway. The company's lead product candidate is Betalutin, a CD37-targeting radioimmunotherapy for the treatment of patients with non-hodgkin lymphoma. Its preclinical development products include Humalutin for treatment of non-Hodgkin's lymphoma; Alpha37, a CD37-targeting radioimmunotherapy for treating chronic lymphatic leukemia; and Multiple fully humanized anti-CD37 antibodies for treatment of haematological cancers and autoimmune diseases. The company is also developing 89Zr-NNV003, a CD37-targeting companion PET diagnostic for detection and dosimetry of CD37 expressing tumors. The company has collaboration agreements with Orano Med; Paul Scherrer Institute; ArevaMed; LegoChem Bio; and Heidelberg Pharma. It also has a research collaboration with the University of Pennsylvania development of a CD37-targeting CAR-T in haematological cancers. The company was formerly known as Nordic Nanovector AS and changed its name to Nordic Nanovector ASA in 2014. Nordic Nanovector ASA was incorporated in 2009 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, NORDIC NANOVECTOR has a trailing twelve months EPS of kr-3.29.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -304.6%.

Yearly Top and Bottom Value

NORDIC NANOVECTOR's stock is valued at kr2.43 at 14:37 EST, way under its 52-week high of kr7.78 and way higher than its 52-week low of kr0.65.

Volume

Today's last reported volume for NORDIC NANOVECTOR is 5797744 which is 125.84% above its average volume of 2567090.

More news about NORDIC NANOVECTOR (NANOV.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com